JP2023546277A - 新規の抗ｃｄ４７抗体及びその使用 - Google Patents

新規の抗ｃｄ４７抗体及びその使用 Download PDF

Info

Publication number
JP2023546277A
JP2023546277A JP2023547735A JP2023547735A JP2023546277A JP 2023546277 A JP2023546277 A JP 2023546277A JP 2023547735 A JP2023547735 A JP 2023547735A JP 2023547735 A JP2023547735 A JP 2023547735A JP 2023546277 A JP2023546277 A JP 2023546277A
Authority
JP
Japan
Prior art keywords
antibody
cancer
cells
immunologically active
active fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2023547735A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023546277A5 (https=
Inventor
ワン ジェンイー
カオ ウェイ
グオ ビンシ
スー コング
Original Assignee
アイ‐マブ バイオファーマ シーオー．， エルティーディー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アイ‐マブ バイオファーマ シーオー．， エルティーディー． filed Critical アイ‐マブ バイオファーマ シーオー．， エルティーディー．
Publication of JP2023546277A publication Critical patent/JP2023546277A/ja
Publication of JP2023546277A5 publication Critical patent/JP2023546277A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2023547735A 2020-10-14 2021-10-14 新規の抗ｃｄ４７抗体及びその使用 Withdrawn JP2023546277A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2020120869 2020-10-14
CNPCT/CN2020/120869 2020-10-14
CN2020122188 2020-10-20
CNPCT/CN2020/122188 2020-10-20
PCT/CN2021/123892 WO2022078465A1 (en) 2020-10-14 2021-10-14 Novel anti-cd47 antibodies and uses thereof

Publications (2)

Publication Number Publication Date
JP2023546277A true JP2023546277A (ja) 2023-11-01
JP2023546277A5 JP2023546277A5 (https=) 2024-12-11

Family

ID=81207683

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023547735A Withdrawn JP2023546277A (ja) 2020-10-14 2021-10-14 新規の抗ｃｄ４７抗体及びその使用

Country Status (12)

Country Link
US (1) US20230399400A1 (https=)
EP (1) EP4229088A1 (https=)
JP (1) JP2023546277A (https=)
KR (1) KR20230114745A (https=)
CN (1) CN116348601A (https=)
AU (1) AU2021360633A1 (https=)
CA (1) CA3198895A1 (https=)
CO (1) CO2023005611A2 (https=)
IL (1) IL302112A (https=)
MX (1) MX2023004223A (https=)
TW (1) TW202229351A (https=)
WO (1) WO2022078465A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017332960B2 (en) 2016-10-20 2019-09-12 I-Mab Biopharma Us Limited Novel CD47 monoclonal antibodies and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017332960B2 (en) * 2016-10-20 2019-09-12 I-Mab Biopharma Us Limited Novel CD47 monoclonal antibodies and uses thereof
WO2019091473A1 (en) * 2017-11-10 2019-05-16 I-Mab Biopharma Co., Ltd. Fusion proteins containing cd47 antibodies and cytokines
WO2020036977A1 (en) * 2018-08-13 2020-02-20 Arch Oncology, Inc. Therapeutic cd47 antibodies
AU2019370754A1 (en) * 2018-10-31 2021-02-04 I-Mab Biopharma Us Limited Novel CD47 antibodies and methods of using same
CA3097443A1 (en) * 2018-11-12 2020-05-22 I-Mab Biopharma Us Limited Fusion proteins containing cd47 antibodies and cytokines

Also Published As

Publication number Publication date
WO2022078465A1 (en) 2022-04-21
KR20230114745A (ko) 2023-08-01
EP4229088A1 (en) 2023-08-23
TW202229351A (zh) 2022-08-01
US20230399400A1 (en) 2023-12-14
MX2023004223A (es) 2023-08-03
AU2021360633A9 (en) 2025-01-09
CA3198895A1 (en) 2022-04-21
CO2023005611A2 (es) 2023-05-29
IL302112A (en) 2023-06-01
CN116348601A (zh) 2023-06-27
AU2021360633A1 (en) 2023-06-15

Similar Documents

Publication Publication Date Title
US11485782B2 (en) Anti-claudin 18.2 antibodies
TWI781120B (zh) Ｐｄ-１之抗體及其用途
JP2024026140A (ja) Ｌｉｌｒｂ２に対する抗体
JP2020517294A (ja) グリピカン３を特異的に認識するコンストラクト及びその使用
US12247060B2 (en) Calreticulin binding constructs and engineered T cells for the treatment of diseases
US20180171017A1 (en) Combined use of immune activators
WO2021047599A1 (en) Humanized anti-claudin 18.2 (cldn18.2) antibodies
US20240279334A1 (en) Anti-cd3 constructs and uses thereof
JP7475275B2 (ja) 二重特異性抗原結合分子及びその使用方法
CN117545779A (zh) 抗ctla-4抗体的用途
JP2023546277A (ja) 新規の抗ｃｄ４７抗体及びその使用
JP2023513059A (ja) 抗ミューラー管ホルモン受容体２抗体及び使用方法
WO2025119313A1 (en) Novel anti-cd47 antibodies and uses thereof
HK40091237A (zh) 新型抗cd47抗体及其用途
HK40014200B (en) Antibodies to t cell immunoreceptor with ig and itim domains (tigit) and uses thereof
HK40014200A (en) Antibodies to t cell immunoreceptor with ig and itim domains (tigit) and uses thereof
HK40034257A (en) Anti-claudin 18.2 antibodies
HK40034257B (en) Anti-claudin 18.2 antibodies

Legal Events

Date Code Title Description
RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20230727

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230727

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230727

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241011

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241011

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20241011

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20241011

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20241125